Aldeyra Therapeutics (ALDX) Short term Debt (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Short term Debt came in at $15.3 million in Q1 2026, little changed on a QoQ basis from $15.2 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Short term Debt (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Short term Debt data on file, last reported at $15.3 million in Q1 2026.
- Quarterly Short term Debt changed N/A year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (changed N/A YoY) and the FY2025 annual result came in at $15.2 million, up 48509.05% from the prior year.
- Short term Debt was little changed at $15.3 million in Q1 2026, from $15.2 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $15.3 million in Q1 2026 to a low of $31372.0 in Q4 2024.
- A 5-year average of $9.7 million and a median of $13.5 million in 2023 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2024 — Short term Debt sank 99.79% — and 2025, when it surged 48509.05%.
- Tracing ALDX's Short term Debt over 5 years: stood at $911763.0 in 2022, then soared by 1561.24% to $15.1 million in 2023, then slumped by 99.79% to $31372.0 in 2024, then surged by 48509.05% to $15.2 million in 2025, then advanced by 0.33% to $15.3 million in 2026.
- The last three Short term Debt figures came in at $15.3 million (Q1 2026), $15.2 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Aldeyra Therapeutics | 93.20 Mn | 93.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.30 Mn |
| Dec 31, 2025 | 15.25 Mn |
| Sep 30, 2025 | 15.20 Mn |
| Jun 30, 2025 | 15.15 Mn |
| Dec 31, 2024 | 31,372.00 |
| Sep 30, 2024 | 279,957.00 |
| Jun 30, 2024 | 15.24 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | 15.15 Mn |
| Sep 30, 2023 | 13.46 Mn |
| Jun 30, 2023 | 5.89 Mn |
| Mar 31, 2023 | 954,325.00 |
| Dec 31, 2022 | 911,763.00 |
| Sep 30, 2022 | 12.45 Mn |
| Jun 30, 2022 | 4.93 Mn |
| Mar 31, 2021 | 5.09 Mn |
| Dec 31, 2020 | 3.66 Mn |
| Sep 30, 2020 | 2.26 Mn |
| Jun 30, 2020 | 894,042.00 |
| Sep 30, 2018 | 465,278.00 |